This study demonstrates the ratio of IP-10 to IL-8 (S2/S0, ratio of changes at 10-12 weeks after treatment to baseline) to predict the response to immunotherapy combined with chemotherapy and evaluate the survival of lung cancer patients and multiple cancer patients. The gene discussed is CXCL10; the disease is lung carcinoma.